Hib Vaccine Protection Beyond Pneumonia
The Haemophilus influenzae type b (Hib) vaccine primarily protects against invasive bacterial diseases including meningitis, epiglottitis, sepsis, cellulitis, septic arthritis, osteomyelitis, and pericarditis—with meningitis being the most significant disease prevented. 1
Primary Diseases Prevented
Meningitis (Most Important)
- Hib was historically the leading cause of bacterial meningitis in children under 5 years before vaccine introduction, accounting for approximately 12,000 cases annually in the United States 1
- The mortality rate from Hib meningitis is approximately 5%, and up to 35% of survivors develop permanent neurologic sequelae including seizures, deafness, and mental retardation 1
- Meta-analysis demonstrates 75% protective efficacy specifically against meningitis (OR 0.25; 95% CI 0.08-0.84) 2
Other Invasive Diseases
The vaccine protects against multiple serious systemic infections caused by Hib:
- Epiglottitis - a life-threatening airway emergency 1
- Sepsis/bacteremia - bloodstream infections 1
- Cellulitis - soft tissue infections 1
- Septic arthritis - joint infections 1
- Osteomyelitis - bone infections 1
- Pericarditis - heart sac infections 1
Overall Vaccine Efficacy
- 84% protective efficacy against all invasive Hib disease (OR 0.16; 95% CI 0.08-0.30) 2
- 69% protective efficacy against pneumonia specifically (OR 0.31; 95% CI 0.10-0.97) 2
- Vaccine introduction has resulted in dramatic reductions: one study in Morocco showed a 75% decrease in confirmed Hib meningitis cases and 93% reduction in minimum incidence after vaccine implementation 3
Important Caveats
Specificity of Protection
- The vaccine ONLY protects against Haemophilus influenzae type b—it does not protect against other H. influenzae types (non-typeable or other serotypes) or other causes of meningitis/sepsis 1
- Other microorganisms causing similar invasive diseases are not covered 1
High-Risk Populations
The vaccine is particularly critical for children at increased risk, including:
- Daycare attendees 1
- Lower socioeconomic groups 1
- Certain racial/ethnic groups (Native Americans, Blacks) 1
- Children with asplenia, sickle cell disease, or antibody deficiency syndromes 1
- Household contacts of cases 1
Timing Considerations
- Peak incidence of Hib meningitis occurs between 6-11 months of age, with 47% of cases occurring by one year of age 1
- Cases of Hib disease may occur in the week after vaccination before protective antibody levels develop 1
- The vaccine should not be used in infants younger than 6 weeks as this may lead to immune tolerance 1